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Morus alba (white mulberry) is native to the northern part of Korea and popularly used as a traditional medicine due to
its numerous health benefits against human’s disease. However, the possibility that M. alba may also affect the cardiovascular
system remains unexplored. This study sought to investigate the vascular protective effects of the root bark extract of M. alba
(MAE). Vascular reactivity was performed in organ baths using isolated rat thoracic aorta, while platelet derived growth factor
(PDGF) induced proliferation and migration of vascular smooth muscle cells (VSMCs) were studied by 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and wound healing assay, respectively. MAE evoked
a concentration dependent vasorelaxation following endothelium-dependent pathway. However, vessel relaxations in response
to MAE were markedly reduced after endothelium removal; treatment of endothelial nitric oxide synthase inhibitor, guanylyl
cyclase inhibitor, and nonspecific potassium channel inhibitor, however, was not altered by cyclooxygenase inhibitor. Furthermore,
MAE also significantly blunted contractile response to vasoconstrictor agent, phenylephrine. Taken together, the current evidence
revealed that MAE is a potent endothelium-dependent vasodilator and this effect was involved in, at least in part, nitric oxide
cyclic-guanosine monophosphate (NO-cGMP) pathway in combination with potassium (K+) channel activation. Moreover, MAE
inhibited proliferation and migration of VSMCs induced by PDGF. Therefore, MAE could be a promising candidate of natural
medicine for preventing and controlling cardiovascular diseases linked with endothelial dysfunction.
1. Introduction
In global scenario, cardiovascular diseases (CVDs) are still
the major cause of morbidity and mortality in developed
nations, while the prevalence is rising rapidly in underde-
veloped country too [1, 2]. The majority of CVDs result
from complications of atherosclerosis or vascular inflam-
mation initiated by endothelial dysfunction and leading
to various pathological conditions like peripheral arterial
disease, coronary heart disease, and hypertension [3]. A
single intimal layer of blood vessel composed of endothelial
cell release, a potent vasodilator, and nitric oxide (NO) to
maintain vascular homeostasis [4, 5]. This homeostasis is
maintained under normal conditions by the cardioprotective
role of endothelial factors. However, toxic insults to the
endothelial cell by various components like oxidative stress,
abnormal cholesterol level, lipid peroxidation, and mitogen
lead to endothelial dysfunction that results in defect in
NO production leading to impaired endothelium-dependent
vasodilation [6–8]. Below the intimal endothelial cell layer,
there are vascular smoothmuscle cells (VSMCs) in adventitial
layer. Migration of VSMCs from tunica adventitia to tunica
intima followed by proliferation at that site contributes to
the growth of atherosclerotic plague and restenosis [9]. Both
migration and proliferation of VSMCs are initiated by num-
ber of inducing factors such as platelet derived growth factors
(PDGF) and tumor necrosis factor alpha (TNF-𝛼) facilitating
atheroma formation in vessel wall [10]. These days, long-
term therapeutic approach to control CVDs by treatment of
modern/western medicine possesses many undesirable side
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effects so traditional natural medicines are considered as
safe and effective alternative to those synthetic drugs [11–
14]. In present context, increasing health issue urged the
researchers to revitalize the natural products and to alleviate
health problems without harming vital functions of the body
[15].
The mulberry tree (Morus alba) has been used for CVD
prevention and treatment for more than a millennium in
eastern countries, particularly in China, Japan, and Korea.
The root bark ofM. alba has beenused in traditionalmedicine
as anti-inflammatory, hypoglycemic, and antibacterial agent
[16]. In addition, the root extract ofM. alba has been reported
to have anticonvulsant and antihypertensive effects in differ-
ent experimental animal models (mice, rats, guinea pigs, and
dogs) [17]. Pharmacological analysis showed that flavonoids,
coumarins, and phenols, such as rutin and quercetin, are
the principal bioactive constituents in M. alba root bark [18,
19]. Rutin and quercetin have been demonstrated to induce
significant vasorelaxation [20, 21]; therefore, we hypothesized
that M. alba root extract may exert vasorelaxation activity.
Previous research has demonstrated that M. alba leaf extract
exerts vasorelaxant effect [22]; however, to the best of our
knowledge, the effect of M. alba root extract on the changes
of vascular tone has not been studied before.
The aim of the present study was to investigate whether
root bark extract of M. alba (MAE) causes endothelium-
dependent vasorelaxation on rat aortic rings and to character-
ize the underlying mechanisms of action. Likewise, the effect
of K+ channel blockers on MAE-induced vasorelaxation was
also investigated. In addition, the effect of MAE on VSMCs
proliferation and migration was also examined.
2. Materials and Methods
2.1. Plant Extract. M. alba was collected from the southern
part of the Jeonnam province of the Republic of Korea. The
dried root bark (20g) was extracted with hot 70% ethanol for
four hours. After subjecting the crude extract to filtration,
the resulting ethanol extract was evaporated using a rotatory
evaporator to obtain a concentrated extract. Finally, the
powder ofMAEwas collected after freeze drying to yield total
extract power of 2.7 g. For vasorelaxation study, MAE was
freshly dissolved in Krebs bicarbonate solution to get desired
concentrations.
2.2. Vascular Reactivity Study. Male Sprague-Dawley rats
of 8 weeks were purchased from Central Lab. Animal Inc.
(Seoul, Republic of Korea). The animals were acclimatized
under controlled environments (room temperature: 23±3∘C,
relative humidity: 55±15%, 12-hour dark and light cycle and
10-20 times ventilations per hour). Rat received commercially
available standard diets (Cargill Agri Purina, Inc., Seongnam,
Republic of Korea) and water. All procedures were approved
by institutional guidelines for the ethical care of animals.
Rats were anesthetized with pentobarbital (120mg kg−1,
i.p.) and the descending thoracic aorta was excised and
immersed in chilled Krebs–Henseleit solution of the follow-















(pH 7.4). The thoracic aorta was
carefully cleaned of adhering fat and connective tissue and
cut into rings about 2-3 mm in length. Aortic rings were
then mounted in standard organ chambers containing 10ml
Krebs–Henseleit at 37∘C and continuously aerated with 95%
O2 +5% CO2 mixture. The tissues were maintained under
tension of 2 g and equilibrated for a period of 90 minutes
before initiating experimental protocols and the solution was
replaced every 15 minutes. Changes in tension were recorded
by isometric transducers connected to a data acquisition
system.
After an equilibration period of 90 minutes, the vessels
were maximally contracted with phenylephrine (1 𝜇M) to
test their contractile capacity. The presence of functional
endothelium was assessed in all preparations by the ability
of acetylcholine (10 𝜇M) to induce more than 80% relaxation
of rings precontracted with phenylephrine (1 𝜇M). In some
experiments, endothelium was removed gently rubbing the
intimal surface of the blood vessel with a pair of forceps;
vessels were denuded of functional endothelium when there
was the absence of acetylcholine relaxant activity.
2.3. Characterization of the Relaxant Effect of Polyphenolic
Compound. The vasorelaxant activity of MAE was mea-
sured in aortic rings with or without functional endothe-
lium precontracted with phenylephrine (1uM) (i.e., 80%
of maximal response obtained in vessels with functional
endothelium). When the contraction to phenylephrine had
stabilized, cumulative concentrations of MAE were added. In
some experiments, rings were induced with inhibitors: L-NA
(N𝜔-nitro-L-arginine, 10 𝜇M: a competitive inhibitor of NO
synthase), ODQ (1H-[1,2,4] oxadiazole [4,3-a] quinoxalin-1-
one, 10 𝜇M: an inhibitor of guanylyl cyclase), TEA (tetraethy-
lammonium, 1mM: nonspecific K+ channel inhibitor), and
INDO (indomethacin, 10 𝜇M: an inhibitor of cyclooxyge-
nase), added to the bath 30 min prior to the phenylephrine
addition.
2.4. Cell Culture. VSMCs were obtained from the Bio-
Whittaker (San Diego, CA). Media were supplemented with
15% fetal bovine serum (FBS), penicillin (100U/mL), strepto-
mycin (100 U/mL), fungizone (250 𝜇g/mL), and L-glutamine
(2 mM). Early passages of VSMCs were grown to 80–90%
confluence and used throughout the experiment. In a typical
experiment, the cells were starved in serum-free culture
medium containing 0.1% FBS for 24 hours.
2.5. VSMCs Proliferation Assay. VSMCs proliferation assay
was assessed by using 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) assay as described previously [23, 24]. VSMCs seeded
into 96 well plates were treated with PDGF-BB (20 ng/ml)
and MAE at various concentrations for additional 24 hours.
Then, MTS solution was added for 4 hours and absorbance
was measured at 540 nm.
2.6. VSMCs Migration Assay. Cell migration assay was per-
formed in IncuCyte (Essen Bioscience) as described previ-
ously [23]. Briefly, 4 × 105 cells were plated on the 96-well




















































Figure 1: Dose response plot of vascular relaxation to phenylephrine in rings with and without endothelium incubated with MAE.
Representative original tracing (a) and corresponding cumulative data (b). Concentration-contraction curves of the phenylephrine on MAE
incubated mice aorta rings with endothelium (c). The contraction response is expressed as the percentage of the phenylephrine-induced
contraction. The relaxation response is expressed as the percentage relaxation of the phenylephrine-induced contraction (100% represent
complete relaxation). Values are the mean ± SEM (n=5). ∗p<0.05, ∗∗P<0.01, and ∗ ∗ ∗P<0.001, significant difference compared with
endothelium-denude rings and control.
ImageLock plates (Essen BioScience) and incubated until
confluent monolayer is formed. Wounds were made by using
the 96-pin wound maker and the cells were treated with and
without PDGF-BB (20 ng/ml) for 48 hours in the presence
and absence of increasing concentrations of MAE. Cell
migration was monitored in real time by IncuCyte software.
2.7. Statistical Analysis. Prism 5.03 (Graph Pad Software Inc.,
San Diego, CA, USA) was used to perform statistical data
analysis. All data were presented as mean ± SEM. Groups
were compared by using ANOVA followed by Turkey’s
multiple comparison test and Bonferroni posttests. P-values
≤ 0.05 were considered statistically significant.
3. Results
3.1. MAE Induces Endothelium-Dependent Relaxation in Rat
Aorta and Prevents Contractile Response in Rat Aorta. MAE
showed endothelium-dependent relaxations in rat aorta,
but only nominal response was seen in those without
endothelium (Figures 1(a) and 1(b)). The effective dose 50
(ED
50
) value of the vasorelaxant effect of MAE was 6.13
± 0.67𝜇g/mL. Moreover, the likelihood that MAE affect
contractile response was studied. MAE exposed to rat aorta
rings for 30 minutes prior to the addition of increasing
concentrations of phenylephrine notably weaken contrac-
tions (Figure 1(c)).These data indicate that MAEmay abolish
contractile response by stimulating the formation of NO.
3.2. MAE Induces Endothelium-Dependent NO-Mediated
Relaxation via the NO-sGC Pathway. Since previous investi-
gations have shown activation of NO/cGMP pathway involv-
ing potassium channel activation causes vasorelaxation in
rat aorta [25], the role of this pathway in the MAE-induced
relaxation was determined in our experiment. Relaxation to
MAE in endothelium intact rings was halted by N𝜔-nitro-
L-arginine (L-NA, a competitive inhibitor of NO synthase)
and 1H-[1,2,4] oxadiazolo [4,3-a] quinoxalin-1-one (ODQ,
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Figure 2: Inhibitory effect of concentration-relaxation curve on the phenylephrine-induced contraction with inhibitors L-NA 10𝜇M (a),
ODQ 10𝜇M (a), TEA 1mM (b), and indomethacin 10𝜇M (c) preincubated 30 minutes prior to phenylephrine. The relaxation response is
expressed as the percentage relaxation of the phenylephrine-induced contraction (100% represent complete relaxation). Values are the mean
± SEM (n=5). ∗P<0.05, ∗∗P<0.01, and ∗ ∗ ∗P<0.001, significant differences compared with control.
an inhibitor of guanylyl cyclase) (Figure 2(a)). In addition,
relaxation to MAE was abolished by tetraethylammonium
(TEA, nonspecific K+ channel inhibitor) (Figure 2(b)). How-
ever, indomethacin (INDO, an inhibitor of cyclooxygenase)
did not affect relaxation caused by MAE (Figure 2(c)). These
findings indicate that endothelium-dependent relaxation by
MAE may follow nitric oxide cyclic-guanosine monophos-
phate (NO-cGMP) pathway including potassium channel
activation.
3.3. MAE Inhibits VSMCs Proliferation and Migration. MAE
inhibit proliferation induced by PDGF-BB dose dependently
at concentrations 1, 10, and 100 𝜇g/ml (Figure 3(b)). MAE at
dose of 1, 10, and 100 𝜇g/ml reduce the proliferation rate to
97%, 90%, and 79% of the control (PDGF-BB treated without
MAE), respectively. We also performed the cytotoxicity assay
to confirm that the inhibitory effects were not due to toxicity
to the cells. MAE had no deleterious effect on the cell viability
up to 100 𝜇g/ml (Figure 3(a)).
MAE at various concentration doses dependently
reduced PDGF-BB induced VSMCs migration for 48 h after
wound making (Figure 4(a)). MAE at concentrations 1, 10,
and 100 𝜇g/ml showed the remarkable inhibition of healing
(41.66%, 25.7%, and 16.96%), respectively, compared with
control at 48 hours (Figure 4(b)).
4. Discussion
In this study, we demonstrate the first finding that the
endothelium-dependent vasorelaxation to MAE may result
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Figure 3: Effect of MAE on HASMCs viability and proliferation. (a) Serum starved HASMCs were pretreated with indicated concentrations
of MAE for cytotoxicity. Values are expressed as mean ± SEM (n=5). (b) Cell proliferation was measured by MTS assay on PDGF-BB induce
HASMCswith or withoutMAE. Values are expressed asmean ± SEM. ∗P<0.05; ∗∗∗P<0.001, significant difference versus control (PDGF-BB
alone).
from an increased formation of NO by endothelial cells
and seems to involve the activation of tetraethylammonium-
sensitive K+ channels.
Our result is in agreement with a previous study where
the aqueous extract from leaves of M. alba induced vasore-
laxation in rat aorta [22]. Although M. alba root extract has
been evaluated for hepatoprotective, neuroprotective activity
[23] and analgesic and anti-inflammatory activity [24], to
the best of our knowledge, the vasoprotective activity of
M. alba root bark extract (MAE) has not been studied
directly before. The present study has reported for the first
time that MAE indeed evoke vasorelaxation in endothelium
intact rat aorta rings dose dependently. Conversely, vasore-
laxation elicited by MAE was all abolished by mechanical
denudation of endothelium and endothelium treated with
L-NAME, an inhibitor of nitric oxide synthase. This study
demonstrates that MAE may stimulate the production of
NO in endothelial cells and that NO might be involved in
the subsequent cyclic-GMP accumulation and endothelium-
dependent relaxation [25, 26]. Accumulating evidence has
indicated thatNO induces vascular smoothmuscle relaxation
through the activation of soluble guanylyl cyclase, resulting
in the accumulation of cyclic-GMP [25–27]; this finding is
supported by the observation in the present study, where
MAE-induced relaxation was all abolished in endothelium
vascular rings treated with ODQ (an inhibitor of soluble
guanylyl cyclase). Therefore, it is highly unlikely that MAE
activated soluble form of guanylyl cyclase in smooth muscle
directly for vasorelaxation. The possibility that endothelium-
derived vasorelaxant factors derived from cyclooxygenase
involved in the vasorelaxant properties of MAE is unlikely
since the endothelium-dependent relaxation caused by MAE
in aortic rings was not affected by indomethacin.
However, the above-mentioned findings were not enough
to rule out the possibility that MAE could also mediate
vasorelaxation via the involvement of other receptors/mecha-
nisms. Calcium (Ca2+) plays a significant role in the synthesis
or release of NO from endothelial cells [28, 29]. It has been
demonstrated that endothelium-mediated vasodilators cause
an increase in inositol triphosphate (IP3) mediated Ca2+
release from intracellular stores which subsequently leads to
the opening of Ca2+ dependent potassium (K+) channels in
endothelial cells [30, 31].
Opening of the Ca2+ dependent K+ channels increases K+
efflux, hyperpolarizes vascular endothelial cells, and thus pro-
vides the driving force for Ca2+ influx into endothelial cells.
In the present study, the endothelium-dependent relaxation
to MAE was attenuated by TEA, a nonselective K+ channel
blocker.These findings demonstrate that MAEmight activate
K+ channels in vascular endothelial cells, which results in an
influx of Ca2+ and subsequent activation of the endothelial
nitric oxide synthase (eNOS). Taken together, the present
findings indicate that MAE causes potent endothelium-
dependent relaxations involving, at least in part, NO/cGMP
pathway and activation of K+ channel.
Endothelium-derived NO seems to play pivotal roles in
vascular endothelium such as maintenance of vascular tone,
modulation of the growth of VSMCs, and decrease in platelet
adhesion/aggregation [32, 33]; therefore, impaired NO pro-
duction is closely linked to the endothelial dysfunction or
injury, which is considered to be a crucial factor in increasing
risk of CVDs [29, 34]. Similarly, endothelium-dependent
vasorelaxation is an important physiological determinant
of normal endothelial cell function; however, an impaired
endothelial function may be involved in the development of
atherosclerosis. Therefore, the identification of plant extracts
with the ability to increase the production of NO by vascular
endothelium can be of great importance for the prevention
and treatment of these CVDs.
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Figure 4: A straight woundwasmade on confluentVSMCs cells in 96-well plates by a commercialWoundMaker. Afterwashing VSMCswith
PBS, cells were treatedwith or withoutMAE and/or PDGF-BB and incubated in IncuCytemachine for 48 hours. Photographs of thewounded
area were scanned immediately at time 0 hours and later at 24 hours and 48 hours after injury (a). The wound density in the migration zone
after 48 hours was calculated in terms of percentage with respect to initial wound area filled by migrated VSMCs. Graphs are presented as
mean ± SEM. ∗∗P<0.01; ∗ ∗ ∗P<0.001, significant difference versus control (PDGF-BB alone).
Additionally, under different aspect we performed
another experiment. VSMCs proliferation and migration
play key role in provoking restenosis and atherosclerosis, so
inhibition of VSMCs proliferation and migration is main
target to control atheroma progression [35, 36]. For in vitro
experiment, PDGF-BB was used to induce proliferation
and chemoattractant for migration of VSMCs as notable
evidence supports the fact that PDGF-BB can remarkably
induce VSMCs migration and proliferation [37, 38]. In our in
vitro model, MAE significantly inhibited PDGF-BB induced
VSMCs proliferation and migration in a dose dependent
manner. Our current study has provided further mechanistic
insight to the vasoprotective effect of MAE and might help
explain its beneficial effect on the cardiovascular system.
Future cardiovascular research involving Morus alba root
bark extract should include the detailed mechanisms of
action, specificity, structure and function relationship, and
therapeutic studies in both animal models and human trials.
Recent studies have indicated that most blood vessels are
embedded in, or surrounded by, perivascular adipose tissue
(vessel supporting connective tissue) that play important role
of vascular homeostasis including maintenance of vascular
function and progression of atherosclerosis [39, 40]. The
outer adventitial layer is a collagen-rich connective tissue
containing adipocytes as well as perivascular nerves [41];
therefore, during cleaning of connective tissues for vascular
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reactivity study, the aortic wall may also be devoid of some
of its components which play a crucial role in vascular
physiology [40–42]. Authors in this study acknowledge the
limitation of this research of not using vessels with complete
vascular wall as control. Taken together, further studies
concerning the effect of MAE on the perivascular fat and
adventitia will provide the more detail evidences of the
protective effect of MAE in vasculature.
5. Conclusion
Our research revealed that Morus alba root extract is a
potent endothelium-dependent vasodilator in part through
endothelial-dependent NO-cGMP pathway including the
activation of TEA sensitive K+ channels. In addition, MAE
attenuated PDGF-BB induced VSMCs proliferation and
migration. This study provides a novel insight to the car-
dioprotective effect of MAE and reinforces use of this plant
with medicinal value for improving cardiovascular health
associated with endothelial dysfunction.
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